0
Articles |

FK 506 `Rescue' Immunosuppression for Obliterative Bronchiolitis After Lung Transplantation

David J. Ross; Michael Ian Lewis; Michelle Kramer; Ashley Vo; Robert M. Kass
Author and Funding Information

Affiliations: From the Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Cardiothoracic Surgery, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Pharmacy, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles

Affiliations: From the Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Cardiothoracic Surgery, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Pharmacy, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles

Affiliations: From the Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Cardiothoracic Surgery, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles,  From the Division of Pharmacy, Cedars-Sinai Medical Center Lung Transplant Program, UCLA School of Medicine, Los Angeles


1997 by the American College of Chest Physicians


Chest. 1997;112(5):1175-1179. doi:10.1378/chest.112.5.1175
Text Size: A A A
Published online

Abstract

Preliminary experience: In a consecutive case series (level V evidence) involving 10 recipients of unilateral lung transplantation (LT) with bronchiolitis obliterans, in conjunction with Fujisawa protocol 93-0-003, the physiologic responses to FK 506 (tacrolimus) "rescue" immunosuppression were assessed. Recipients were 22±18 months post-LT and demonstrated progressive allograft dysfunction that was refractory to pulsed-dose methylprednisolone therapy. All recipients received induction immunosuppression with Minnesota antilymphocyte globulin (10 to 15 mg/kg/d) for 5 to 10 days, cyclosporine (CsA) (whole-blood Abbott TDXTM> fluorescence polarization immunoassay (Abbott Inc, Abbott Park, IL)=600 to 800 ng/mL), azathioprine (2 mg/kg/d), and prednisone (tapered to 0.2 mg/kg/d). The "rescue" regimen consisted of oral FK 506 adjusted to maintain a whole-blood Abbott IMXTM microparticle enzyme immunoassay (Abbott Inc, Abbott Park, IL) of 10 to 15 ng/mL with an initial increase in prednisone (1.0 mg/kg/d) during conversion that was subsequently tapered to 0.2 mg/kg/d. Spirometry was performed monthly in accordance with accepted American Thoracic Society criteria. Recipients were classified in accordance with the International Society for Heart and Lung Transplantation (ISHLT) "Working Formulation for Standardization of Nomenclature and for Clinical Staging of Chronic Dysfunction in Lung Allografts" as stages Ib (n=2), IIb (n=4), and IIIb (n=4) upon entry to the protocol. The ΔFEV1/month relationships during CsA- and FK 506-based regimens were analyzed by linear regression and compared by signed rank test (p<0.05).

Results: The ΔFEV1/month slopes were −0.0687±0.0221 and +0.0300±0.033 L/mo (mean±SEM) for CsA and FK 506, respectively (p=0.037). Although no significant spirometric improvement was noted in most recipients, no further decline in FEV1 occurred after conversion to FK 506. Recipients with less severe chronic dysfunction (ie, obliterative bronchiolitis [OB] stages Ib and IIb) stabilized their spirometric indexes at higher levels. Two recipients with OB stage IIIb died of hypercapnic respiratory failure at 6 and 8 months after conversion.

Conclusions: The ΔFEV1/mo slopes stabilized after FK 506 conversion. Earlier conversion may be beneficial in stabilizing FEV1 at a higher plateau. Significant economic impact may be anticipated with FK 506 compared to alternative cytolytic strategies for OB. However, multicenter prospective controlled investigations are necessary to further address the potential role of FK 506 after LT (level I evidence). Furthermore, the ISHLT "Staging of OB Syndrome" may have significant clinical implications vis-à-vis prognosis and potential therapies.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543